The use of platinum and etoposide chemotherapy as guided first‐line treatment has been unchanged for decades.[8] Meanwhile, the 5‐year overall survival (OS) rate of ES‐SCLC remains less than 5% due to rapid progression and early metastasis.[9] Unlike in non‐SCLC (NSCLC), targeted drugs against vascular endothelial growth factor (VEGF), insulin‐like growth factor 1 receptor, mechanistic target of rapamycin kinase, epidermal growth factor receptor, and hepatocyte growth factor have not achieved success in SCLC. This evidence concerns the gene EGFR and small cell lung carcinoma.